Generex Biotechnology Corporation (NASDAQ: GNBT), a biopharmaceutical company, has a diversified product portfolio designed to deliver innovative products to treat patients with cancer. DNA/RNA-based Medicines and Small Molecules are the two major programs that anchor the Company’s research platform. Ganite® (gallium nitrate injection) is the company’s leading drug in the Small Molecule program. Ganite is exclusively marketed in the U.S. to treat symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. For further information, visit the Company’s web site at www.genta.com.
- 17 years ago
QualityStocks
Generex Biotechnology Corporation (NASDAQ: GNBT)
Tags Rodman & Renshaw
Related Post
-
Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): Anticipating Tomorrow’s Imaging Standards Today
CMS proposal keeps CT radiation quality measure voluntary, highlighting ongoing debate around dose safety and…
-
Silvercorp Metals Inc. (NYSE-A/TSX: SVM) Still Looking to Grow, Files US$400M Base Shelf Prospectus
Silvercorp has a stated mandate to grow through acquisitions. The company’s profitable operations in China…
-
PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Moves Forward with Three Nova Scotia Community Solar Projects, Construction Targeted for Spring 2026
The company is advancing three Nova Scotia community solar projects, in Sydney, Brooklyn, and West…